Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer
Authors
Carr, T. H.Adelman, C.
Barnicle, A.
Kozarewa, I.
Luke, S.
Lai, Z.
Hollis, S.
Dougherty, B.
Harrington, E. A.
Kang, J.
Saad, F.
Sala, N.
Thiery-Vuillemin, A.
Clarke, Noel W
Hodgson, D.
Barrett, J. C.
Affiliation
AstraZeneca, Cambridge CB4 0WG, UKIssue Date
2021
Metadata
Show full item recordCitation
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, et al. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer Vol. 13, Cancers. MDPI AG; 2021. p. 5830.Journal
CancersDOI
10.3390/cancers13225830PubMed ID
34830984Type
Articleae974a485f413a2113503eed53cd6c53
10.3390/cancers13225830
Scopus Count
Collections
Related articles
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
- Authors: Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F
- Issue date: 2018 Jul
- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
- Authors: Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ
- Issue date: 2023 Oct
- Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
- Authors: Dong B, Yang B, Chen W, Du X, Fan L, Yao X, Xue W
- Issue date: 2022 May 23
- Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.
- Authors: Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q, Ding L, Liu W, Dong S, Zhao T, Yu Y, Guo C, Yao X, Peng B, Yang B
- Issue date: 2024 Mar 7
- Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
- Authors: Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M
- Issue date: 2023 Jan 4